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Abstract
Background:  Cisplatin is widely used for chemotherapy of head and neck squamous cell
carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are
still unclear. The aim of this study was to identify the expression of genes related to cisplatin
resistance in oral squamous cell carcinoma cells.
Methods: A cisplatin-resistant cell line, Tca/cisplatin, was established from a cisplatin-sensitive cell
line, Tca8113, which was derived from moderately-differentiated tongue squamous cell carcinoma.
Global gene expression in this resistant cell line and its sensitive parent cell line was analyzed using
Affymetrix HG-U95Av2 microarrays. Candidate genes involved in DNA repair, the MAP pathway
and cell cycle regulation were chosen to validate the microarray analysis results. Cell cycle
distribution and apoptosis following cisplatin exposure were also investigated.
Results: Cisplatin resistance in Tca/cisplatin cells was stable for two years in cisplatin-free culture
medium. The IC50 for cisplatin in Tca/cisplatin was 6.5-fold higher than that in Tca8113. Microarray
analysis identified 38 genes that were up-regulated and 25 that were down-regulated in this cell line.
Some were novel candidates, while others are involved in well-characterized mechanisms that
could be relevant to cisplatin resistance, such as RECQL for DNA repair and MAP2K6 in the MAP
pathway; all the genes were further validated by Real-time PCR. The cell cycle-regulated genes
CCND1 and CCND3 were involved in cisplatin resistance; 24-hour exposure to 10 μM cisplatin
induced a marked S phase block in Tca/cisplatin cells but not in Tca8113 cells.
Conclusion: The Tca8113 cell line and its stable drug-resistant variant Tca/cisplatin provided a
useful model for identifying candidate genes responsible for the mechanism of cisplatin resistance
in oral squamous cell carcinoma. Our data provide a useful basis for screening candidate targets for
early diagnosis and further intervention in cisplatin resistance.
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Background
Head and neck squamous cell carcinoma (HNSCC) is a
major public problem, frequently associated with devas-
tating functional and cosmetic consequences for patients.
More than 500,000 new cases are estimated to occur
worldwide every year [1] and two thirds of patients
present with locally advanced lesions and/or regional
lymph node involvement. The benefits of chemotherapy
for patients with advanced head and neck squamous cell
carcinoma, demonstrated by recent meta-analyses of ran-
domized studies, include reduction of the distant metas-
tasis rate, improved survival rate and preservation of
organ function, whether or not combined with local/
regional treatment [2]. Cisplatin is one of the most potent
chemotherapeutic agents currently in use, exerting its
cytotoxic action through the formation of intra-strand
DNA crosslink adducts [3]. However, the therapeutic ben-
efits of apoptosis resulting from cisplatin-induced DNA
damage can be attenuated, and the resistance that ensues
is a major limitation of cisplatin-based chemotherapy.
The molecular mechanisms underlying the acquisition of
resistance to cisplatin are not fully understood. Multiple
mechanisms have been described in gastric, colonic and
ovarian cancer cells [4-6]. It is believed that the molecular
signature defining the cisplatin-resistant phenotype dif-
fers among tumors and generally involves many factors.
In order to elucidate the cisplatin resistance mechanisms
in oral squamous cell carcinoma, we established a cispla-
tin-resistant cell model with progressively acquired chem-
oresistance, Tca/cisplatin, which was derived from a
cisplatin-sensitive cell line. We used Affymetrix HG-
U95Av2 microarrays to analyze the differences in gene
expression patterns between this resistant cell line and its
sensitive parent line, with the aim of identifying genes
associated with cisplatin resistance in this subtype of
HNSCC. When maintained in cisplatin-free culture
medium for two years, Tca/cisplatin still preserved a stable
cisplatin-resistant character. Compared with previously
reported cell lines, analysis of these Tca/cisplatin cells dis-
closed some novel drug-resistance associated genes [12-
14].
Methods
Establishment of cisplatin-resistant cells
Cisplatin resistance in Tca/cisplatin, a variant cell line
derived from Tca8113, was developed by exposure to cis-
platin for 24 months, starting at 1 μM and ending at 10
μM. Despite massive cell death among the sensitive
Tca8113 cells under treatment, the cultures were main-
tained by regular changes of medium and intermittently
increasing the cisplatin concentration until the surviving
cells recovered a normal growth pattern. Before testing,
the Tca/cisplatin cells were continuously maintained in
cisplatin free RPMI-1640 medium (Invitrogen, CA) sup-
plemented with 10% fetal bovine serum (Gibco, USA) for
two years.
Growth inhibition
Growth inhibition was determined by a MTT assay
repeated six times. In brief, cells were seeded in 96-well
plates at a density of 2 × 103 cells/well (200 μl/well) for 24
h before use. The culture medium was replaced with fresh
medium containing different concentrations of cisplatin
ranging from 0 to 160 μM for 48 h. Water-soluble tetrazo-
lium MTT (Sigma-Aldrich, USA) was added (20 μl). After
a further 4 h incubation, the supernatant was discarded
and the purple crystals were re-suspended in 200 μl of
DMSO. The absorbance of each well was read at 570 nm
on an ELISA XL (BIOHIT, BP800, Finland). Growth rate
was calculated as the ratio of the absorbance of the exper-
imental well to that of a blank well. The IC50 (concentra-
tion of drug that results in 50% of control value) was
calculated as previously described [7].
Apoptosis assay
Apoptosis induced by treatment with different concentra-
tions of cisplatin for 48 h was assayed using an Annexin
V-FITC/PI Apoptosis Detection Kit (BD Pharmingen,
USA) following the manufacturer's protocol; assays were
repeated three times. The results were analyzed using Cell
Quest (BD Pharmingen, USA) and flow cytometry (FACS-
calibur, Becton-Dickinson Co., USA) was used to distin-
guish the cells as viable (Annexin V-/PI-), early apoptotic
(Annexin V+/PI-) or late apoptotic (Annexin V+/PI+).
Cisplatin accumulation
For cisplatin accumulation experiments, cells were
exposed to 200 μM cisplatin for 2 h and then harvested.
The drug exposure was relatively brief, so that the contri-
bution of net platination of DNA could be isolated and
the effect of DNA repair reduced, as discussed previously
[8]. Total DNA was extracted. Platinum concentrations
were determined using Inductively Coupled Plasma
Atomic Emission Spectrometry (ICP, Thermo Jarrell Ash,
IRIS Advantage 1000, USA) at the Department of Instru-
mental Analysis Center of Shanghai Jiao Tong University;
measurements were repeated three times.
RNA preparation and gene expression
Total RNA was extracted and analyzed on HG-U95Av2
Affymetrix oligonucleotide arrays (Affymetrix, CA, USA)
containing 12,626 probe sets for human genes, as
described previously [9]; analyses were repeated three
times. Gene expression profiles were compared between
Tca/cisplatin and Tca8113, with Tca8113 cells as baseline,
using GeneChip Suite 5.0 software (Affymetrix, CA, USA).
All the genes represented on the microarray were globally
normalized and scaled to a signal intensity of 500. Fold
changes were calculated by comparing transcriptsBMC Cancer 2006, 6:224 http://www.biomedcentral.com/1471-2407/6/224
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between the sensitive and the acquired-drug-resistant cell
lines. In GeneChip Suite 5.0 software, Wilcoxon's test was
used to identify detected (present or absent) and changed
(increased or decreased) calls. This provided a basis for
statistical determination of whether or not a transcript
was expressed and whether it was relatively increased,
decreased or unchanged.
Real-time PCR
Several interesting genes including MAP2K6, RECQL,
CCND1, CCND3, ABCB1,  ABCC2  and  GST-Pi  were
selected to validate the results of microarray analysis, as
described previously [10]. Total RNA was extracted and
reverse transcribed to cDNA (Life Technologies, USA). The
primer sets and product lengths are listed in table 1. PCR
was carried out according to the standard protocol of
SYBR Premix Ex Taq (TaKaRa, Japan) using Real-time PCR
Equipment (ABI 7300, ABI, USA). To quantify changes in
gene expression, the ΔΔCt method was used to calculate
the relative fold changes, normalized against glyceralde-
hyde-3-phosphate dehydrogenase.
Western blotting
Whole-cell extracts were prepared in cell lysis buffer (M-
Per, Pierce, USA). The first antibodies were: mouse mono-
clonal anti-CCND1 (Cell Signaling, clone DCS6, dilution
1:2000), rabbit polyclonal anti-CCND3 (Proteintech
Group, dilution 1:1000), mouse monoclonal anti-ABCB1
(Calbiochem, clone C219, dilution 1:1000) and mouse
monoclonal anti-GST-Pi (Abcam, clone BD1340, dilution
1:1000). Signals were visualized using Supersignal West
Pico Chemiluminescent Substrate (Pierce). Mouse mono-
clonal anti-β-actin (Sigma, clone AC-15, dilution
1:10000) was used throughout as loading control.
Immunohistochemical staining
Fresh specimens of primary oral squamous cell carcinoma
were collected aseptically from the Department of Oral &
Maxillofacial Surgery, Ninth People's Hospital, between
June 2003 and July 2005. The specimens were minced
with scissors and passed through a 200 pores/cm2 steel
mesh to prepare tumor cell suspensions. Each suspension
was cultured with or without 10 μM CDDP for 72 h.
Growth inhibition was evaluated using a modified MTT
assay to assign each sample to the cisplatin-resistant or the
cisplatin-sensitive group [11,12]. Immunohistochemical
staining was performed on formalin-fixed, paraffin-
embedded, 4 μm-thick tissue sections using the standard
SP method. First antibodies were: mouse monoclonal
anti-CCND1 (Cell Signaling, clone DCS6, dilution 1:100)
and rabbit polyclonal anti-CCND3 (Proteintech Group,
dilution 1:100). The staining intensity in each section was
evaluated by three pathologists and graded according to
the average percentage of positive cells in three randomly
selected fields: – (0–5% cells stained), + (5%-20% cells
stained), ++ (20%-50% cells stained) and +++ (>50% cells
stained).
Cell cycle analysis
Cells in exponential growth were cultured in 10 μM cispl-
atin for 6, 12 or 24 h, then washed twice in PBS and fixed
in 70% cold ethanol overnight. Cell pellets were resus-
pended in 1 mg/ml RNase (Sigma-Aldrich, USA) at 37°C
for 30 min, followed by staining with 50 μg/ml propid-
ium iodide (Sigma-Aldrich, USA). For each sample, 104
cells were analyzed by flow cytometry (FASCalibur, BD,
USA). Results were expressed as the percentage of cells in
each phase of the cell cycle (Mean ± SD).
Statistics
An ANOVA test was used to examine the statistical differ-
ences in growth inhibition and apoptosis rates between
Tca/cisplatin and Tca8113 cells. Student's t test was used
to determine the statistical differences between these two
cell lines in cisplatin accumulation and Real-time PCR
results. Immunohistochemical staining results were ana-
lyzed by a Mann-Whitney U test. P < 0.05 was considered
statistically significant. A significance analysis of microar-
rays algorithm (SAM) was used to identify significant dif-
ferences in gene expression between these two cell lines
(triplicate results), with the estimated false discovery rate
(FDR) setting as 1 and the response type setting as two
class unpaired.
Results
Cisplatin-resistant phenotype of Tca/cisplatin cell line
The Tca/cisplatin cell line was obtained by stepwise selec-
tion from its sensitive parent cell line over a period of two
years. At the beginning of induction, cell growth was
strongly suppressed. However, at the end of induction, the
Table 1: Primer lists of Real-time PCR
Gene Name Primer Sequence Product
MAP2K6 5' GAGTCTGGGCATCACG 3' 103bp
5' CGATGGCTCCTCTACC 3'
RECQL 5' CAATGGCTGGAAAGGAGGTA 3' 112bp
5' AATGGGCAAATGACGAGTGT 3'
CCND1 5' GCTGGAGCCCGTGAAAAAGAG 3' 326bp
5' GGATTGGAAATGAACTTCACA 3'
CCND3 5' CTGCCTCCAGGAACCACA 3' 146bp
5' GCTTGACTAGCCACCGAAAT 3'
ABCC1 5' AAATGCAGCTGATGAATCCAAAA 3' 271bp
5' TTGCAAATGCTGGTTGCA 3'
ABCC2 5' CACTTCAGCGAGACCG 3' 246bp
5' GGACAGAACAAAGCCAAC 3'
GST-pi 5' TTTCGCCGCCGCAGTCT 3' 122bp
5' TCCACGGTCACCACCTCCTC 3'
GAPDH 5' AACGGATTTGGTCGTATTGGG 3' 516bp
5' AGTCTTCTGGGTGGCAGTGAT 3'BMC Cancer 2006, 6:224 http://www.biomedcentral.com/1471-2407/6/224
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derived cells proliferated fairly rapidly. After further main-
tenance for up to 60 passages in cisplatin-free RPMI1640
supplemented with 10% fetal bovine serum, the resistant
cells exhibited stable biological characteristics: the popu-
lation doubling time was 29.93 h, while that of the parent
cell line was 38.82 h. The drug-resistant cells were stable
for two years in cisplatin-free culture medium.
Sensitivity to cisplatin
Cells were treated with different concentrations of cispla-
tin for 48 h and dose-response curves were plotted as
shown in Figures 1A and 1B. Dose-dependent antiprolif-
erative activity and apoptosis (Figure 1C) were observed
in both cell lines; however, the resistance of Tca/cisplatin
to cisplatin was 6.5 fold higher than that of the parental
Tca8113 cells, as measured by the IC50 values for cisplatin
over 72 h treatment [13]: 26.69 ± 3.42 μM with 95% con-
fidence interval [19.46, 38.43], and 4.11 ± 1.21 μM with
95% confidence interval [2.07, 7.14], respectively.
Cisplatin accumulation in Tca/cisplatin and Tca8113 cells
Intracellular accumulation of cisplatin was compared
between Tca/cisplatin and Tca8113 cells by determining
the amount of platinum in DNA. Time-dependent accu-
mulation was observed (Figure 2), and after 2 h exposure,
Tca8113 had 2.15 times as much DNA-associated cispla-
tin as Tca/cisplatin cells.
Different gene expression profiles in Tca/cisplatin and 
Tca8113
The Affymatrix HG-U95Av2 microarray contains 12626
probe sets, most of which have previously been character-
ized in term of function or disease association. In order to
distinguish valid signals from background noise, three
replicates were performed using independently isolated
RNA samples for each cell line, and a total of 6 hybridiza-
tions were analyzed. Scatter plots of the normalized sig-
nals were constructed and the average of the correlation
coefficients for replicates was 0.951, suggesting good con-
sistency. SAM was used to identify genes that were signifi-
cantly differently expressed between these two cell lines,
with FDR setting = 1. As shown in Table 2, a total of 63
probe sets were selected, among which 38 genes were up-
regulated and 25 down-regulated in the Tca/cisplatin cell
line. On the basis of the Gene Ontology list, these 63
genes were primarily classified according to potential
function into metabolism-related genes, cell cycle-related
genes, transcription factors, substrate transporters, signal
transduction-related genes, oncogenes, and so on. The
down-regulated genes included those involved in cell
cycle arrest, regulation of cell proliferation, nucleic acid
binding and protein metabolism, while the up-regulated
genes mostly included those involved in cell cycle regula-
tion (CCND1, ASNS), DNA repair (RECQL), small mole-
cule non-selective transport (ITPR1), protein synthesis
(GARs), transcription (ID1, ID2) and oncogenes (c-syn,
FGFR3, RAB31). The up-regulated genes could result in
cell cycle acceleration, increased proliferation, enhanced
DNA metabolism and synthesis, altered molecular trans-
port and elevated transcriptional activity; Tca/cisplatin
had a shorter population doubling time (29.93 h) than
the parental cell line (38.82 h).
Confirmation of differential expression by Real-time PCR 
and Western blotting
Seven genes – MAP2K6 in the MAP pathway, the DNA
repair-related gene RECQL, the cell cycle-related genes
CCND1 and CCND3, ATP-binding cassette family mem-
bers ABCB1 and ABCC2, and the cellular detoxification-
related gene GST-Pi – were selected for further verification
of the microarray results by Real-time PCR. Also, the
expression of CCND1, CCND3, ABCB1 and GST-Pi pro-
teins was further tested by Western blotting, exploiting
their functional linkages to biochemical mechanisms that
could be related to cisplatin resistance. As shown in Figure
3, which represents the results of three independent exper-
iments, both the Real-time PCR (Figure 3A) and Western
blotting (Figure 3B) analyses confirmed the microarray
results.
Cell cycle distribution
Analysis of the gene expression profiles suggested that the
cell cycle-related genes CCND1 and CCND3 were differ-
ently expressed in Tca/cisplatin and Tca8113 cells. We
therefore analyzed the cell cycle distribution further fol-
lowing cisplatin exposure. As shown in Figure 4, pro-
longed exposure to cisplatin for 6, 12 or 24 h induced a
significant difference in cell cycle distributions in the two
cell lines. A predominant S phase block was observed at
24 h in the Tca/cisplatin cells; this was 74.35%, signifi-
cantly higher than the 42.91% in the Tca8113 cells.
Expression of CCND1 and CCND3 in primary oral 
squamous cell carcinoma
Clinical samples were classified into cisplatin-sensitive
and resistant groups on the basis of growth inhibition as
indicated by the MTT assay [11]. The cutoff point for the
sensitive group was above 50%, while for the resistant
group it was below 30% [12]. Samples with growth inhi-
bition rates between 30%-50% were excluded to elimi-
nate bias. In total, 50 samples qualified for inclusion in
the final analysis, 25 in each group. As Figure 5 shows,
CCND1 and CCND3 staining was mainly observed in the
nuclei. Using the scoring method described above for
CCND1 staining, 48% of samples in the sensitive group
were graded as '-', 28% as '+', 16% as '++' and 8% as '+++';
while only 20% in the resistant group were graded as '-',
24% as '+', 44% as '++' and 12% as '+++'. For CCND3
staining, 24% of samples in the sensitive group were
graded as '-', 16% as '+', 44% as '++' and 16% as '+++';BMC Cancer 2006, 6:224 http://www.biomedcentral.com/1471-2407/6/224
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while in the cisplatin resistant group 60% were '-', 8% '+',
28% '++' and 4% '+++'. In other words, up-regulation of
CCND1 and down-regulation of CCND3 were observed
in the resistant group whereas the opposite changes were
noted in the sensitive group. The Mann-Whitney U test
confirmed statistically significant differences in CCND1
(P = 0.021) and CCND3 (P = 0.013) between these two
groups.
Response of Tca/cisplatin and Tca8113 cells to cisplatin Figure 1
Response of Tca/cisplatin and Tca8113 cells to cisplatin. A: Dose-growth rate curve plotted from the MTT assay 
results. Both cell lines displayed dose-dependent growth inhibition, but the Tca/cisplatin cells were more resistant to the anti-
proliferative activity of cisplatin (P = 0.0000, ANOVA analysis). Each point was the mean of six independent experiments. B: 
Dose-viability curve was plotted from the Annexin-V/PI assay results. There was a dose-dependent decrease in viability in both 
cell lines, but the decrease was more rapid in the Tca8113 cells (P = 0.0000, ANOVA analysis). Each point was the mean of three 
independent experiments. C: Scatter plots of Annexin V/PI staining. As the cisplatin dose increased, the apoptosis rates 
(UR+LR) also gradually increased, but the increase was more rapid in Tca8113 cells than in Tca/cisplatin cells (P = 0.0000, 
ANOVA analysis). Each figure represents three independent experiments.
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Discussion
Here we established an isogenic cisplatin-resistant variant
from the oral squamous cell carcinoma cell line Tca8113
so that we could compare their gene expression profiles
directly. It is clear from our results that the cisplatin-resist-
ant cell line, Tca/cisplatin, has a genome-wide expression
profile that differs from the Tca8113 line. Our microarray
analysis results revealed 63 differently expressed genes,
including some previously reported genes that have been
related to cisplatin resistance (CCND1, ID1, ID3, GCA,
etc.), and also some novel ones such as TRIM29, N33,
GRAS and GPI [14-16]. Considering that Tca/cisplatin and
Tca8113 cells have identical genetic backgrounds, we sup-
posed that these differently expressed genes are related to
cisplatin resistance and the differences might shed light
on the mechanism of resistance to this chemotherapeutic
agent. Nevertheless, extensive investigation of the detailed
effects of these genes in conferring the cisplatin-resistance
phenotype on oral squamous cell carcinomas is needed to
provide potential strategies for reversing the resistance
[16,17].
It is well known that cisplatin cytotoxicity is attributable
to the formation of various DNA adducts that trigger a cel-
lular response culminating in apoptosis. Correspond-
ingly, the major resistance mechanisms that limit the
extent of DNA damage include reduced drug uptake by
the ABC transporter, increased drug inactivation by cellu-
lar detoxification, increased DNA adduct repair by DNA
repair systems, etc. [18]. We observed a 2.15-fold higher
cisplatin accumulation in Tca8113 cell DNA than in Tca/
cisplatin cell DNA after 2 h treatment with cisplatin. We
further investigated the expression of ABCB1, which is the
first ABC transport identified [19], ABCC2, which medi-
ates the active efflux of glutathione-conjugated cisplatin
[20], and GST-Pi. No difference was found between our
cell lines by SAM analysis of the microarray results, which
were further validated by Real-time PCR. However, over-
expression of RECQL, a DNA helicase involved in various
types of DNA repair including mismatch, nucleotide exci-
sion and direct repair, was increased in our cisplatin-
resistant cells, though this is the first suggestion that it is
associated with cisplatin resistance [21]. An enhanced
DNA repair rate would also attenuate the apoptotic proc-
ess induced by the formation of DNA adducts of cisplatin,
which has been demonstrated in several studies in murine
and human tumor cell lines [22-26]. Because our samples
were cultured under cisplatin-free conditions for 2 years,
the lack of difference in ABCB1, ABCC2 and  GST-Pi
expression may also reflect their characteristics as tran-
sient drug-resistance genes.
Cell cycle arrest is an initial cellular response to DNA
damage. After treatment with 10 μM cisplatin for 24 h, a
marked S phase block was observed in Tca/cisplatin cells
but not in Tca8113 cells. Cell cycle arrest is necessary to
enable the nucleotide excision repair complex to remove
the DNA adducts and to promote cell survival. Only when
repair is incomplete, as would be the case when damage is
extensive, will cells undergo apoptosis [27]. Cisplatin-
induced S phase block may be involved in DNA adduct
repair in cisplatin resistant cells, which has also been
reported in the cisplatin-resistant A2780-cis cell line when
compared with sensitive A2780 cells [28]. Owing to the
complex relationship between cell cycle arrest and cyto-
toxicity, the underlying mechanisms of cell cycle arrest
and drug resistance have not been fully deciphered. Cell
cycle progression is strictly regulated by the activation of a
series of cyclins and cyclin-dependent kinases [29].
Among these, CCND1 is a cell cycle regulatory factor that
modulates a critical step in cell cycle control. In Tca/cispl-
atin cells, an interestingly altered pattern of expression of
the cell cycle genes CCND1  and  CCND3  was found:
CCND1 was up-regulated while CCND3 was down-regu-
lated. CCND1 and CCND3 usually show overlapping
expression patterns, yet their functions are not totally
redundant; for example, in human mammary epithelial
cells, CCND1 expression peaks in G1 and declines before
the S phase, while CCND3 expression rises later in G1 and
remains elevated in S phase [30]. CCND1 is preferentially
associated with cyclin-dependent kinases 4 and 6, which
inactivate the retinoblastoma tumor suppressor protein
via phosphorylation, thereby overcoming the Rb-medi-
Platinum accumulation on DNA in Tca/cisplatin and Tca8113 Figure 2
Platinum accumulation on DNA in Tca/cisplatin and 
Tca8113. DNA was extracted from Tca/cisplatin cells (blue) 
and Tca8113 cells (pink) after treatment with 200 μM cispla-
tin for 0, 30, 60 and 120 min. The platinum concentration in 
isolated DNA was measured by ICP. Each point is the mean 
of three independent experiments. Significant differences 
were observed at 60 min (P = 0.008, Student's t test) and 120 
min (P = 0.002, Student's t test), which are marked with 
asterisks.
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Table 2: Genes differently expressed in cisplatin resistant SCC cells
Classification Gene Change Fold a
Metabolism AKR1C3 -3.96
ALDH3B1 -2.14
GPI -2.00
NNMT -2.00
MAOB -2.00
NAGA 2.14
FLJ12443 2.14
SLC27A2 2.30
SLC2A3 2.83
GARS 2.00
QPRT 2.14
Cell cycle CCND3 -2.83
CCND1 4.29
ASNS 2.83
Transcript factor TRIM29 -2.00
ZFP36 -2.83
CREM 2.83
ETV5 4.29
ID1 2.00
ID3 4.00
CAMTA2 2.00
Transport MUC1 -2.14
ATP1B1 -2.00
TCIRG1 -2.30
COX8 -2.46
KPNB2 2.30
Signal transduction MAP2K6 -2.30
IGFBP3 -5.66
PDLIM1 2.00
IGFBP7 2.30
PDE8B 2.14
IL13RA1 3.03BMC Cancer 2006, 6:224 http://www.biomedcentral.com/1471-2407/6/224
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ARF6 2.14
GCA 7.06
PIP5K1A 2.00
ITPR1 2.64
Oncogene FYN 2.83
FGFR3 3.03
RAB31 2.83
EMS1 -2.14
Others CHST2 -2.83
C1S -2.83
H2AFO -2.30
PPL -2.30
TGM2 -2.30
KIAA0992 -2.14
SELENBP1 -2.00
H2BFB -2.00
DKFZp564J0323 -2.00
PON2 -2.00
FUSIP1 2.00
DDOST 2.00
ODAG 2.14
RECQL 2.14
DMD 2.14
G1P2 2.30
RAFTLIN 2.30
SEMA3F 2.30
N33 2.30
TUBA3 2.30
KRT7 2.46
BC008967 3.25
ITGA1 3.48
a: mean of triplicate measurements.
Table 2: Genes differently expressed in cisplatin resistant SCC cells (Continued)BMC Cancer 2006, 6:224 http://www.biomedcentral.com/1471-2407/6/224
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ated blockade of G1 and facilitating G1-S progression.
Overexpression of CCND1 has been linked to tumor
resistance to cisplatin in fibrosarcoma cell lines and in
breast, pancreatic, colon and lung cancers [31]. Wang and
colleagues [32] also reported that antisense CCND1
enhances the sensitivity of head and neck squamous cell
carcinoma cells to cisplatin. So it was reasonable to
hypothesize that the inverse expressions of CCND1 and
CCND3 might participate in the cisplatin resistance of
Tca/cisplatin cells. Furthermore, our preliminary results
from 50 oral squamous cell carcinoma samples showed
that the inverse expression pattern of CCND1 and
CCND3 correlates with cisplatin sensitivity.
The measurement of gene expression can provide infor-
mation on regulatory mechanisms, biochemical path-
ways, cellular control mechanisms and potential targets
for intervention and therapy in a variety of disease states
[15]. Our results support the hypothesis that multiple spe-
cific genes contribute to the development of cisplatin
resistance in squamous cell carcinoma. Microarray analy-
sis of the model system for differentially expressed genes
involved in cisplatin resistance in squamous cell carci-
noma has revealed a variety of genes, including some
putatively common drug-resistance-related genes, and
this provides a rational basis for determining which path-
ways are appropriate for further study and which molecu-
lar targets are potential targets for gene therapy [16,17].
Further exploration based on these findings will provide
new insights into the complicated molecular events of
drug resistance. Having determined the existence of such
differences, the next question is: to what extent are these
gene expression alterations related to cisplatin-resistance?
There may be heterogeneity in the gene expression pro-
files among malignant tumors of a particular histopatho-
logical grade and chemotherapeutic agent resistance
potential. Studies of the molecular mechanisms regulat-
ing these changes would help to identify prognostic
biomarkers and treatment targets for HNSCC chemother-
apy.
Conclusion
The Tca/cisplatin and Tca8113 cell lines are useful models
for identifying candidate genes responsible for the mech-
anism of cisplatin-resistance in oral squamous cell carci-
noma. Sixty-three genes related to cisplatin-resistance
were identified. Among these, decreases in cell cycle arrest
genes and increase in oncogenes, cell cycle regulation
gene and genes involved in metabolism and synthesis led
to the cell cycle acceleration, increased proliferation rate
and resistance to cisplatin-induced apoptosis in Tca/cispl-
atin cells. CCND1 and CCND3 seemed to be closely
involved in cisplatin resistance. The data from this study
provide useful clues to screen candidate targets for early
diagnosis and intervention in cisplatin-resistance.
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Validation of genechip results by Real-time PCR and Western  blotting Figure 3
Validation of genechip results by Real-time PCR and 
Western blotting. A: Using Real-time PCR, we validated 
the expression of MAP2K6, RECQL, CCND1, CCND3, ABCB1, 
ABCC2 and GST-Pi transcripts in both cell lines and calculated 
the relative fold changes by normalizing against GAPDH 
expression. Ratios of transcripts in Tca/cisplatin cells and 
Tca8113 cells generally showed the same expression differ-
ences as microarray analysis. Each column represents the 
results of an independent experiment (repeated three times). 
B: Using Western blotting, we further validated the expres-
sion of CCND1, CCND3, ABCB1 and GST-Pi proteins in 
both cell lines, using β-actin as a loading control. The results 
also show alterations similar to those found using the gene-
chip. Each figure represents three independent experiments. 
(a: Tca/cisplatin cells, b:Tca8113 cells).
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Effects of 10 μM cisplatin on Tca/cisplatin and Tca8113 cell cycle distribution Figure 4
Effects of 10 μM cisplatin on Tca/cisplatin and Tca8113 cell cycle distribution. After exposure to 10 μM cisplatin for 
0, 6, 12 and 24 h, cells were harvested and stained with propidium iodide to assess cell cycle distribution by FACS analysis. 
Representative time course for Tca/cisplatin and Tca8113 cells in different phases of the cell cycle (one time course each) are 
shown. The results are expressed as mean ± SD of three independent experiments. A predominant S phase block of 74.35% 
was observed at 24 h in the Tca/cisplatin cells, significantly higher than the 42.91% in the Tca8113 cells.
Tca/cisplatin-0hr
G1˖56.44f5.2%
G2/M˖8f2.31%
S˖35.56f4.74%
Tca/cisplatin-6hr
G1˖55.34f6.1%
G2/M˖9.89f2.91%
S˖34.77f3.1%
Tca/cisplatin-12hr
G1˖66.33f6.1%
G2/M˖1.67f0.84%
S˖33.67f3.33%
Tca/cisplatin-24hr
G1˖25.65f6.74%
G2/M˖0.43f0.26%
S˖74.35f7.9%
Tca8113-0hr
G1˖61.68f5.3%
G2/M˖3.47f1.3%
S˖34.85f6.7%
Tca8113-6hr
G1˖23.78f4.3%
G2/M˖30.68f4.8%
S˖45.54f7.2%
Tca8113-12hr
G1˖73.39f6.54%
G2/M˖1.11f0.56%
S˖22.61f2.2%
Tca8113-24hr
G1˖54.23f5.6%
G2/M˖2.87f0.28%
S˖42.91f3.1%
Expression of CCND1 and CCND3 in primary oral squamous cell carcinoma Figure 5
Expression of CCND1 and CCND3 in primary oral squamous cell carcinoma. Fifty specimens of primary oral squa-
mous cell carcinoma were collected and classified into resistant (red column) and sensitive (blue column) groups on the basis 
of growth inhibition as assessed by the modified MTT assay, 25 cases in each group. A. Immunstaining results were ranked 
according to the staining percentage: '-' (0–5%), '+'(5%-20%), '++' (20%-50%) and '+++' (>50%). B. Mann-Whitney U test 
showed that CCND1 (P = 0.021) and CCND3 (P = 0.013) were differentially expressed in primary tumors in a manner consist-
ent with their drug resistance patterns.
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